Pages
Products
CAG-GFP Lentivirus

CAG-GFP Lentivirus

Cat.No. :  LV00958Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Cat. No. LV00958Z
Description This lentivirus contains GFP under the control of CAG (CBA) promoter.
Target Gene GFP
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Packaging of the vector genome is a critical step in the production of infectious, replication-defective viral particles, i.e., lentiviral vectors. This is achieved by trans-complementation of all essential viral functions in packaging cells, where the genes encoding these functions are transfected as separate plasmids. Packaging techniques have evolved over time. In the first SIN lentiviral vector generation system, the vector genome contained the Tat-dependent complete HIV-1 long terminal translation (LTR) and most of the HIV-1 genome and was co-transfected in packaging cells with two plasmids, the first expressing the gag, pol, vif, vpr, vpu, nef, tat, and rev genes and the second expressing the env gene. The HIV-1 env gene, encoding a glycoprotein with HIV-1-specific tropism, was replaced by the env gene of bovine vesicular stomatitis virus (VSV-G), which binds to the ubiquitous low-density lipoprotein (LDL) receptor. VSV-G pseudotyping greatly expanded the tropism and utility of lentiviruses (LVs) and made it possible to produce high-titer LV preparations by ultracentrifugation. After repeated iterations, the so-called third-generation packaging system was developed, which has all HIV accessory genes removed and is designed to package SIN vectors transcribed from a heterologous promoter, usually from cytomegalovirus (CMV), in a Tat-independent manner. This system further improves the biosafety of viral production by splitting the structural gag/pol and env genes into two separate plasmids, thereby reducing the possibility of generating replication-competent lentivirus (RCL) through plasmid recombination during the packaging process. Analysis of samples from 26 different clinical trials using third-generation LVs showed the absence of RCLs, confirming that this vector design significantly improves the biosafety of LVs and the versatility of clinical applications.

Nonhuman primates (NHPs) are considered the most valuable model for the study of human transgenic (Tg) diseases, as NHPs more closely resemble human pathology compared to rodents. Previous studies have reported the generation of Tg NHPs that ubiquitously overexpress transgenes using various promoters. Here, researchers evaluated four putative ubiquitous promoters, namely, the cytomegalovirus (CMV) immediate early enhancer and chicken β-actin (CAG), elongation factor 1α (EF1α), ubiquitin C (UbC), and CMV, using an in vitro differentiation system of cynomolgus monkey embryonic stem cells (ESCs). While the EF1α promoter promoted Tg expression more than the other promoters in undifferentiated pluripotent ESCs, the CAG promoter was more effective in differentiated cells such as embryoid bodies and ESC-derived neurons. When both CAG and EF1α promoters were used to generate Tg monkeys expressing green fluorescent protein (GFP), the CAG promoter promoted GFP expression in skin and hematopoietic tissues more than EF1α-GFP Tg monkeys. Therefore, the CAG promoter appears to be the most suitable for ubiquitous and stable expression of transgenes in differentiated tissues of Tg cynomolgus monkeys and for establishing human disease models.

Because the CAG and EF1α promoters drove transgenic expression most strongly in differentiated and undifferentiated cells, respectively, lentiviral vectors carrying a GFP-encoding gene under the control of these promoters were constructed (Figure 1A) and injected into oocytes. Eight days after fertilization, the blastocysts infected with EF1α-GFP lentivirus showed stronger GFP fluorescence than did those treated with the CAG-GFP lentivirus (Figure 1B), consistent with the idea that the EF1α promoter drives stronger Tg expression than the CAG promoter in undifferentiated ESCs. After transfer to recipient foster mothers, three CAG-GFP Tg and three EF1α-GFP Tg offspring were obtained (Figure 1C). GFP fluorescence was observed on the facial skin of the CAG-GFP CE1894M, CE1993F and CE1984F Tg offspring, while GFP fluorescence was not detected on the facial skin of the EF1α-GFP Tg monkey (CE1881M), and GFP fluorescence was observed on the facial skin of the CE1886M and CE1887F. It is notable that GFP fluorescence was detected in a CAG-GFP Tg monkey carrying just one copy of the gene for GFP (CE1894M), whereas it was not detected in the EF1α-GFP Tg monkey carrying four copies of the transgenes (CE1881M) (Figure 1C). Thus, in ESC-derived differentiated cells, the CAG promoter drives transgene expression more strongly than the EF1α promoter, and the activity of the CAG promoter in the skin is stronger than that of the EF1α promoter overall (Figure 1).

Figure 1. Generation of GFP Tg cynomolgus monkeys.Figure 1. Generation of GFP Tg cynomolgus monkeys. (Seita Y, et al., 2019)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Excellent product quality

CAG-GFP Lentivirus has very stable product quality, providing us with an efficient tool for research and greatly improving the success rate of experiments.

United States

05/15/2021

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction